Changes in cardiac function associated with Bruton’s Tyrosine Kinase Inhibitor
The development of novel targeted therapies to inhibit various oncogenic kinases are a research intensive area. Bruton’s Tyrosine Kinase (BTK) Inhibitors have emerged as highly efficacious therapies for the treatment of haematological malignancies. However, emerging evidence suggests that these therapies may be associated with adverse cardiovascular events, including new-onset atrial fibrillation (AF) in 3.5–6.5% of subjects which represents an incidence 3- to 10-fold that expected for age.
The cause of AF is not known. Furthermore, AF is a common consequence of abnormalities of more diffuse heart problems but the possibility that BTK inhibitors affects cardiac function more broadly has not been thoroughly investigated. The Sports Cardiology laboratory endeavours to examine the effects of BTK inhibitors on cardiac function. The use of novel sensitive functional measures such as strain imaging and exercise cardiac magnetic resonance imaging (CMR) will predicate the presence of fibrosis and the functional reserve of ventricles and atria.